• 1
    Kane JM. Pharmacologic treatment of schizophrenia. Biol. Psychiatry 1999; 46: 13961408.
  • 2
    Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 2004; 38: 21222127.
  • 3
    Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. Suppl. 2000; 407: 8386.
  • 4
    Simpson GM. A brief history of depot neuroleptics. Journal of Clinical Psychiatry 1984; 45: 34.
  • 5
    Kane JM, Aguglia E, Altamura AC, Ayuso GJL, Brunello N, Fleischhacker WW. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998; 8: 5566.
  • 6
    Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics. Drugs 2003; 65: 493512.
  • 7
    Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 2004; 4: 5357.
  • 8
    Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am. J. Psychiatry 2002; 159: 103108.
  • 9
    Kane JM, Eerdekens M, Lindenmayer JP et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003; 160: 11251132.
  • 10
    Fleischhacker W, Eerdekens M, Karcher K. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003; 64: 12501257.
  • 11
    Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 2004; 26: 19942002.
  • 12
    Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004; 1: 91100.
  • 13
    Turner M, Eerdekens E, Jacko M, Eerdedens M. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int. Clin. Psychopharmacol. 2004; 19: 241249.
  • 14
    Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry 2004; 19: 219225.
  • 15
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596601.
  • 16
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC, 1994.
  • 17
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499502.
  • 18
    Wilkie A, Preston N, Wesby R. High dose neuroleptics: Who gives them and why? Psychiatr. Bull. 2001; 25: 179183.
  • 19
    Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: Evidence from a routine therapeutic drug monitoring service. Ther. Drug Monit. 2005; 27: 103106.
  • 20
    Bai YM, Chen TT, Lin WK, Chang WH, Wu B, Hung CH. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection. J. Clin. Psychopharmacol. 2007; 27: 306308.
  • 21
    Wilson W. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J. Psychiatr. Pract. 2004; 10: 393401.
  • 22
    Spina E, Avenoso A, Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001; 153: 238246.
  • 23
    Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 2006; 16: 233240.
  • 24
    Nesvåg R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr. Scand. 2006; 114: 2126.
  • 25
    Lane HY, Chiu WC, Chang WH. Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels. J. Clin. Psychiatry 2000; 61: 209214.
  • 26
    Lane HY, Chang WH. The role of the cytochrome P450 system in the metabolism of psychotropic drugs. Taiwanese J. Psychiatry 1997; 11: 345356.
  • 27
    Chou WH, Yan FX, Robbins-Weilert DK et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 2003; 49: 542551.
  • 28
    Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93102.
  • 29
    Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8: 2736.
  • 30
    Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry 2006; 163: 396401.
  • 31
    Nyberg S, Farde L, Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch. Gen. Psychiatry 1997; 54: 953958.
  • 32
    Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: A cognitive perspective. Can. J. Psychiatry 2005; 50: 247257.
  • 33
    Moller H-J, Llorca P-M, Sacchetti E, Stephen DM, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 2005; 20: 121130.
  • 34
    Akio H, Takehiko O. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry Clin. Neurosci. 2005; 59: 556562.
  • 35
    Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. Adv. Ther. 1999; 16: 7888.
  • 36
    Masand P. Using newer antipsychotic agents in primary care. Primary Psychiatry 1997; 58: 6468.
  • 37
    Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin. Pharmacokinet. 1985; 10: 315333.
  • 38
    Chang WH, Lin SK, Juang DJ et al. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr. Res. 1993; 9: 3540.
  • 39
    Conlon L, Fahy TJ, Toole RO, Gilligan J, Prescott P. Risperidone in chronic schizophrenia: A detailed audit, open switch study and two-year follow-up of patients on depot medication. Eur. Psychiatry 2002; 17: 459465.
  • 40
    Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J. Clin. Psychopharmacol. 2008; 28: 210213.
  • 41
    Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can. J. Psychiatry 2006; 51: 531539.
  • 42
    Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr. Res. 2004; 70: 117.
  • 43
    Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186: 572578.
  • 44
    Lieberman J, Stroup T, Hsiao J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353: 12091223.
  • 45
    Lai YC, Chiu CC, Chen CH, Huang MC. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone. J. Clin. Psychopharmacol. 2007; 27: 523524.